Filing Flows › DexCom (DXCM) › R&D spending
DexCom (DXCM) R&D spending by quarter
DexCom's R&D spending was $162M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $145M (Q1 2025) to $162M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $162M | +6% | +3% |
| Q2 2026 | $153M | +5% | +3% |
| Q1 2026 | $145M | -2% | +0.1% |
| Q4 2025 | $148M | -6% | — |
| Q3 2025 | $158M | +6% | — |
| Q2 2025 | $148M | +2% | — |
| Q1 2025 | $145M | — | — |
Q3 2026 at a glance
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
Questions
What is DexCom's R&D spending?
DexCom's R&D spending was $162M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has DexCom's R&D spending changed?
Over the last 7 quarters it ranged from $145M (Q1 2025) to $162M (Q3 2026).